NCI cancer diagnostic imaging group would fund clinical, cost-effectiveness trials.
This article was originally published in The Gray Sheet
Executive SummaryNCI PROPOSAL FOR COLLABORATIVE CANCER IMAGING RESEARCH would fund a five-year cooperative agreement for a total projected cost of $22 mil. The National Cancer Institute proposal to help industry fund clinical trials of promising imaging techniques was approved by the NCI Board of Scientific Advisors on March 4. NCI expects funding to be available by fiscal year 1998 (beginning Oct. 1).
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.